[Featured Stock] Strong Performance of Bio Stocks Following AACR Impact at US Cancer Research Society

[Asia Economy Reporter Hyunseok Yoo] The stock prices of pharmaceutical and bio companies confirmed to present clinical pipeline data at the 2020 American Association for Cancer Research (AACR) are rising together.

As of 10:17 AM on the 5th, ToBeSoft was trading at 1,780 KRW, up 4.09% (70 KRW) from the previous trading day. Other bio companies such as Enzychem Lifesciences (0.30%), ABL Bio (7.35%), Genexine (8.29%), and Eutilex (7.32%) are also on the rise.

The AACR, held from April 24 to 29 next month in San Diego, USA, is one of the three major cancer societies in the United States with over 40,000 members from more than 90 countries. ToBeSoft, Enzychem Lifesciences, ABL Bio, Genexine, Eutilex, GI Innovation, and Chong Kun Dang are scheduled to present their anti-cancer research achievements at AACR.

ToBeSoft plans to present preclinical research results on immuno-oncology drugs based on Alloferon and Allostatin. Alloferon is a substance prescribed over one million times in Russia, verifying its safety, and Allostatin is a new drug candidate that enhances the anti-cancer effect of Alloferon. Both substances have excellent immune-enhancing effects and are being developed as therapeutic agents through combination prescriptions with existing anticancer drugs.

Enzychem Lifesciences will showcase two research results on the mechanism of action of the new drug EC-18 in combination immuno-oncology therapy (EC-18-based ICI) and radiation-induced oral mucositis (EC-18-202). ABL Bio will also disclose preclinical research results of the bispecific antibody immuno-oncology drugs ABL503 and ABL111, which have immune checkpoint regulatory functions, including research related to immuno-oncology using the bispecific antibody platform (Grabody T).